Rhadinoviruses establish chronic infections of clinical and economic importance. Several show respiratory transmission and cause lung pathologies. We used Murid Herpesvirus-4 (MuHV-4) to understand how rhadinovirus lung infection might work. A primary epithelial or B cell infection often is assumed. MuHV-4 targeted instead alveolar macrophages, and their depletion reduced markedly host entry. While host entry was efficient, alveolar macrophages lacked heparan -an important rhadinovirus binding target -and were infected poorly ex vivo. In situ analysis revealed that virions bound initially not to macrophages but to heparan + type 1 alveolar epithelial cells (AECs). Although epithelial cell lines endocytose
binding until heparan is engaged [24] . Thus, gL -gp70 -MuHV-4 infects poorly both in vitro and in vivo, unless gp150 is disrupted also [33] . The Bovine Herpesvirus-4 gp150 homolog, gp180, is functionally similar [34] . While most transformed epithelial cells express abundant heparan, most in vivo epithelia do so only basolaterally [35] . Thus, heparan-dependent host entry by incoming, apical virions is not necessarily straightforward. The olfactory neuroepithelium, which we have analysed previously [17] , unusually expresses both basolateral and apical heparan. The genital epithelium lacks apical heparan [36] ; entry here may depend on epithelial trauma, as MuHV-4-infected cells are seen underneath rather than in the stratified squamous epithelium [18] . We asked which cell type MuHV-4 targets in the lungs and how this relates to heparan binding. Our aim was to understand better rhadinovirus entry into new hosts and so establish a rational basis for infection control.
Results

Viral lytic antigens appear in lung myeloid cells before epithelial cells
Four days after i.n. MuHV-4 inoculation, viral antigens were expressed in morphologically typical type 1 AECs, whose extensive cytoplasmic projections line the lung air spaces (Fig. 1A ). This tropism was confirmed by co-staining lungs for viral antigens and the type 1 AEC marker podoplanin (PDP) [37] (Fig. 1B) -at 4 days post-inoculation >50% of viral antigen + cells were PDP + (Fig. 1C) . The morphologically distinct remainder expressed the macrophage / granulocyte marker CD68 [38] [39] [40] . However at 1 day post-inoculation viral antigens were confined to CD68 + cells. Therefore while infection spread to type 1 AECs, it appeared to start in macrophages or granulocytes.
Incoming virions infect alveolar macrophages
MuHV-4-immune sera recognize mainly lytic antigens. As much early lung infection is latent [41] , we tracked host entry more comprehensively via lytic cycle-independent [42] eGFP expression from a viral HCMV IE1 promoter ( Fig. 2A) . At 1 day post-inoculation, 238/238 eGFP + cells on lung sections of 3 mice were CD68 + . None was PDP + . MuHV-4 rendered incapable of uncomplemented lytic spread by disruption of its ORF50 transactivator (ORF50  -) showed a similar eGFP distribution: 78/78 eGFP + cells on lung sections from 5 mice expressed CD68, and none expressed PDP (Fig. 2B ). Therefore CD68 + cells were direct infection targets.
More than 80% of eGFP + cells expressed also the tissue macrophage marker F4/80 [39] and the alveolar macrophage / dendritic cell marker CD11c [38, 40] (Fig. 2C ). Macrophage populations are heterogeneous and often not clearly demarcated [38] , but combined CD11c, CD68 and F4/ 80 expression argued that most infected cells were alveolar macrophages. The lack of HCMV IE1-driven eGFP expression in type 1 AECs at day 1 post-inoculation established that they were uninfected rather than just slow to initiate lytic infection. We saw also no eGFP expression in B cells at day 1 by either eGFP + wild-type (WT, >100 eGFP + cells counted from 3 mice) or eGFP + ORF50 -MuHV-4 (>50 eGFP + cells counted from 3 mice) (S1 
Genetic tagging shows early virus replication in myeloid cells
Viral lytic gene expression suggests but does not prove lytic replication. To determine how alveolar macrophage infection contributed to virus production we infected lysM-cre mice with MuHV-4 in which cre-mediated recombination switches fluorochrome expression from A C57BL/6 mice were given i.n. MuHV-4 (10 4 p.f.u.). After 4 days lung sections were stained for viral antigens with a polyclonal rabbit serum (brown) and co-stained with hematoxylin (blue). Arrows show infected cells with characteristic type 1 AEC morphology. B C57BL/6 mice were given i.n. MuHV-4 (10 5 p.f.u.). At early (day 1) or peak (day 4 for this infection dose) infection, lung sections were stained for viral lytic antigens (green in merge), PDP (type 1 AECs, red in merge) and CD68 (macrophages, white in merge). Nuclei were stained with DAPI (blue in merge). Higher magnification day 4 images show example viral antigen + PDP + and CD68 + cells. At day 1 only CD68 + cells were mCherry + (red) to eGFP + (green) (MHV-RG) [26] . LysM-cre mice express cre from the myeloid lysozyme locus [43] . To identify cre + lung cells we crossed them with a reporter strain in which cre activates Zsgreen expression from a widely expressed promoter [44] . , consistent with published data [43] , but lung cells expressing neutrophil markers (Gr-1 or myeloperoxidase) were not (S2 Fig). They also lacked eGFP expression by HCMV-IE1-eGFP + MuHV-4.
Therefore we interpreted MHV-RG switching in lysM-cre mice as an infection of alveolar macrophages. Some switching in lung dendritic cells was possible, but they express little lysM [43] or CD68 [39] , so there was no other indication that dendritic cells were a significant target for incoming virions. The MHV-RG recovered from lysM-cre lungs at 1 day post-inoculation was >96% eGFP + ,
indicating that essentially all of it had passed through an alveolar macrophage (Fig. 3A) . Surprisingly the MHV-RG recovered after 4 days showed only 85% switching. This reduction in % switched virus with time was consistent and statistically significant (Fig. 3B ), suggesting that virions could also enter the lungs without infecting a macrophage, but that virus production was then delayed. We confirmed myeloid infection as the predominant route by infecting CD11c-cre mice (Fig. 3C ), as alveolar macrophages (and dendritic cells) are CD11c + [38] . Again the virus recovered from lungs after 1 day was >96% eGFP + , and that recovered after 4 days was >85% eGFP + .
The prominent viral lytic antigen expression in type 1 AECs at day 4 post-inoculation ( Fig. 1) but not day 1 implied that they receive and amplify virus from alveolar macrophages. Their lack of HCMV IE1-driven or EF1α-driven eGFP expression at day 1 (Figs. 2, S1) excluded acute infection. Day 1 MHV-RG-infected lung sections (Fig. 3D) Fig. 3A-3C . Either virions eventually penetrated AECs, or macrophages licenced AEC infection without becoming infected themselves, for example by recycling virions from early endosomes to exosomes and releasing them in a licensed form [45] .
Alveolar macrophage depletion compromises host entry
Most lung macrophages express CD169 [46] , so we used CD169-DTR mice [47] to test their importance for host entry (Fig. 4 . %eGFP + gives the proportion of viruses exposed to cre. The input virus was 0% eGFP + . Circles show individual mice, crosses show means. B A repeat experiment showed the same high recombination at both time points, but higher at day 1 than day 4. Across both trials the % eGFP + was significantly higher at day 1 than at day 4 (p<0.002 by Student's 2-tailed unpaired t test). C Lung sections of mice infected as in A were stained for eGFP (green in merge), mCherry (red in merge) and PDP (white in merge). Nuclei were stained with DAPI (blue). At day 1 all fluorescent cells were PDP -and morphologically lung macrophages. Of these >90% were eGFP + . At day 4 there were both eGFP + and mCherry + PDP + cells. Images are presentative of 12 sections from 3 mice. D CD11c-cre mice, which express cre in alveolar macrophages, were infected with MHV-RG as in A. Most recovered virus showed evidence of exposure to cre, again with more switching at day 1 than at day 4 (p<0.03 by Student's 2-tailed unpaired t test). played a crucial role in virus acquisition, for which lineage-distinct bone marrow-derived myeloid cells [48] did not substitute.
Alveolar and other macrophages are infected poorly ex vivo
Host entry via lung macrophages was unexpected, as MuHV-4 infects the lungs efficiently [49] and myeloid cells poorly [26] . The cell-free virions used for in vivo infection poorly infected ex vivo lung macrophages, peritoneal macrophages or the monocyte line RAW-264 (Fig. 5A) . Virus stocks containing cell debris infected macrophages with reasonable efficiency. However cell-associated virus infections would occur only after host entry. Efficient alveolar macrophage infection by cell-free virions evidently depended on their normal tissue context.
MuHV-4 that lacks heparan binding due to gp70 and gL disruption infects mice i.n. 100-fold less well than the WT, unless its gp150, which inhibits heparan-independent binding, is disrupted too [33] . This result implies that host entry requires heparan engagement. We confirmed it by pre-incubating WT virions with soluble heparin (Fig. 5B ). Seroconversion by virus-specific serum IgG ELISA-the the most sensitive measure of low dose infection in immunocompetent mice [33] -was reduced 10-100-fold by the heparin treatment. Pre-incubating virions with heparin also reduced NMuMG epithelial cell infection 100-fold (Fig. 5C ). However, while low dose heparin inhibited RAW-264 monocyte infection better than NMuMG cell infection-presumably because RAW-264 cells have little heparan for virion binding to start with [26] -there was also a heparin-resistant component of infection, such that the maximal inhibition was only 4-fold. Therefore the efficiency of lung infection and its by Student's unpaired 2-tailed t test) and an equivalent number of epithelial cells (p>0.2), indicating a specific barrier to macrophage infection by cell-free virions. B Cell-free eGFP + MuHV-4 (10 4 p.f.u./ml) was incubated with heparin (1mg/ml in DMEM, 2h, 23°C) or in DMEM alone (control), then given i.n. to C57BL/6 mice in 30μl at the doses shown (8 mice per group). After 14 days the mice were tested for infection by ELISA of MuHV-4-specific serum IgG. Incubation with heparin reduced significantly infection rates at 0.1 p.f.u. (p<0.03 by Fisher's exact test) and 1 p.f.u. (p<0.01). C Cell-free eGFP + MuHV-4 was incubated with different heparin concentrations (2h, 23°C) then added to NMuMG epithelial cells (0.5 p.f.u./cell) or RAW-264 monocytes (5 p. f.u./cell). EGFP expression was determined after overnight culture as in A. Each point shows mean ± SD of triplicate cultures. Virus without heparin gave 65.3% eGFP + NMuMG cells and 13.1% eGFP + RAW-264 cells. Heparin inhibited RAW-264 infection significantly better than NMuMG cell infection at <30μg/ml, but significantly worse at >100μg/ml (p<0.001 by Student's 2-tailed unpaired t test, comparing % inhibition for each cell type).
doi:10.1371/journal.ppat.1004761.g005 A Lungs of naive mice were stained for PDP (green in merge), CD68 (white in merge), and sulfated heparan with mAb 10E4 (red in merge). Nuclei were stained with DAPI (blue). Two example images are shown, representative of 10 sections from 2 mice. Heparan co-localized with PDP (type 1 AECs) and not with CD68 (alveolar macrophages). B Lung sections as in a were stained for PDP, CD68, and unsulfated heparan with mAb NAH46 (red in merge). Two example images are shown, representative of 10 sections from 2 mice. Heparan co-localized with PDP and not with CD68. C Lung sections as in a were stained for PDP, collagen IV (white in merge), and sulfated heparan with mAb 10E4. Heparan and collagen IV showed equivalent susceptibility to inhibition by heparin both suggested an initial interaction with epithelial cells rather than macrophages.
Alveolar epithelial cells express heparan; alveolar macrophages do not
To identify heparan + cells in the lungs we stained sections with mAb 10E4, which recognizes sulfated heparan [50] (Fig. 6A) , and with mAb NAH46, which recognizes non-sulfated heparan [51] (Fig. 6B ). Staining by both mAbs co-localized with PDP (type 1 AECs) and not with CD68 (alveolar macrophages). To distinguish apical from basolateral heparan, we co-stained sections for the alveolar basement membrane component collagen IV (Fig. 6C ). Sulfated heparan (mAb 10E4) co-localized completely with collagen IV and so was just basolateral. Unsulfated heparan (mAb NAH46) also co-localized largely with collagen IV. However there were also NAH46 + surfaces abutting the air spaces that lacked collagen IV. Therefore specifically unsulfated heparan was accessible to incoming virions on the apical AEC surface.
Incoming virions bind to type 1 AECs but accumulate in macrophages
One day after WT MuHV-4 inoculation, viral antigens were evident as isolated dots-presumably virions. Of these 94. 
Neutralizing virions for host entry
The γ-herpesviruses transmit from immune carriers and elicit salivary antibody responses [55] . Therefore shed virions may carry glycoprotein-specific antibodies. Also virions entering immune hosts or vaccinees could acquire antibodies before reaching mucosal surfaces. Therefore how bound antibodies affect host entry is important to understand. In vitro, immune sera inhibit MuHV-4 epithelial and fibroblast infections, but fail to inhibit and even enhance myeloid infection due to productive IgG Fc receptor (FcR)-mediated uptake [56] . This reflects that sera neutralize in vitro mainly by blocking cell binding, for which FcR binding can substitute. We tested 2 MuHV-4 glycoprotein-specific mAbs for their effect on lung infection: 8F10, which binds to gH/gL and blocks its interaction with heparan [57] , and SC-9E8, which binds near the gB fusion loops and blocks membrane fusion [58] (Fig. 8) .
In vitro both mAbs inhibited fibroblast infection, but while SC-9E8 inhibited RAW-264 monocyte infection 8F10 enhanced it (Fig. 8A) . Enhancement reflects that FcR binding improves significantly cell-free MuHV-4 attachment to RAW-264 cells [56] . In vivo virion capture via type 1 AECs was efficient already, so here mAb 8F10 simply failed to neutralize (Fig. 8B, 8C ). By contrast mAb SC-9E8, which neutralizes independent of cell binding [58] , was effective at blocking host entry. Most transformed epithelial cell lines display both sulfated and unsulfated heparan and are bound by both gp70 and gH/gL [33] . However only gH/gL binds well to unsulfated heparan (10E4 -NAH46 + ) [17] , as displayed by the apical alveolar epithelium (Fig. 6) . Accordingly, an additional block of gp70 heparan binding by mAb LT-6E8 [33] did not affect host entry (Fig. 8C) .
To understand better the in vivo fate of 8F10-opsonized virions, we exposed WT and ORF50 -eGFP + MuHV-4 to mAb 8F10 or not, gave them i.n., and 1 day later stained lung sections for eGFP expression (Fig. 8D) . Pre-incubation with 8F10 increased significantly the number of eGFP + lung macrophages. Epithelial infection was unaffected, consistent with this occurring via macrophages rather than directly. Pre-incubating WT MuHV-4 with mAb 8F10 or not and staining lungs for virion antigens 5h after i.n. inoculation (Fig. 9) showed that 8F10 reduced significantly the virion binding to PDP + cells without compromising their accumulation in CD68 + cells. Therefore blocking cell binding with antibody was insufficient to block host entry, because it merely diverted virions to where they were already going: macrophages.
Discussion
How rhadinoviruses first infect new hosts has been little explored. Even for lymphocryptoviruses there is considerable uncertainty. In vitro analyses have focussed on epithelial cell and lymphocyte infections. However MuHV-4, which enters the upper respiratory tract via olfactory neurons, entered the lungs via alveolar macrophages. Most entry models envisage a target cell with a specific binding receptor that is infected readily ex vivo. Alveolar macrophages lacked the key initiator of MuHV-4 binding-heparan-and were infected poorly ex vivo. These data suggest a new paradigm, in which virions with a sophisticated fusion machinery can exploit normal host pathways for entry. One such pathway appeared to be particle scavenging by alveolar macrophages; another was opsonization-dependent endocytosis. Thus, in vivo neutralization had to act post-binding. As immune sera neutralize MuHV-4 mainly by blocking cell binding [56] , this explains their limited capacity to block host entry [59] .
In vivo cell diversity and interaction provide a dimension lacking from most cell lines. Cooperative infections are one reflection of this and are a recurring theme in γ-herpesvirus host colonization: EBV can infect epithelial cells by transfer from B cells [60] , and MuHV-4 infects olfactory sustentacular cells via binding to adjacent neurons [17] . The homeostatic interactions of macrophage with other cell types [61] make them prime candidates to participate in co-operative infections. Here, epithelial heparan binding licensed virions for macrophage infection, and interaction with macrophages in turn licensed epithelial infection.
How might epithelial cell binding license macrophage infection? The MuHV-4 gp150 promotes virion release from heparan-deficient surfaces by inhibiting heparan-independent binding [24] . (Inhibition of EBV epithelial cell infection by gp350 [60] may analogously promote virion release.) Thus, initiating MuHV-4 infection requires heparan for binding and to engage gp150. A lack of heparan normally limits macrophage infection by non-opsonized, cell-free virions. If heparan is provided, or if the need for heparan is bypassed by gp150 disruption or by virion opsonization, then infection works well [26] . Therefore type 1 AECs licensed macrophage infection by their apical heparan capturing virions and engaging gp150. How might virion interaction with myeloid cells license epithelial infection? The next step in MuHV-4 entry after binding is endocytosis. Virions lacking gL show an endocytic defect that can be reproduced by gH/gL-directed neutralization, implying that gH/gL engages a proendocytic ligand [57] . (This ligand is not heparan as distinct mAbs block gH/gL heparan binding and virion endocytosis.) Thus, a paucity of pro-endocytic ligands may strand heparanengaged virions on type 1 AECs. (By contrast the olfactory epithelium shows no barrier to virion uptake after binding [17, 26] .) The MuHV-4 gB and gH change conformation between endocytosis and fusion; fusion itself involves further changes [53, 62] . Myeloid-derived virions display constitutively the intermediate, post-endocytic forms of gB and gH and overcome a post-binding block to B cell infection [26] . We envisage that they overcome the post-binding block to type 1 AEC infection in the same way. The tropism-associated gB and gH conformation changes occur in early endosomes, whereas fusion occurs in late endosomes [63] . Therefore virions sorted from myeloid early endosomes to exosomes could be released in a tropismswitched form without a need for myeloid infection. This would explain how follicular dendritic cells transfer MuHV-4 from marginal zone to follicular B cells without becoming infected [27] . A similar cycling through alveolar macrophage endosomes would explain delayed type 1 AEC infection without prior macrophage infection.
Myeloid cells have roles in host colonization by several lymphotropic viruses [64, 65] including the human MuHV-4 ortholog, KSHV [66, 67] . Although MuHV-4 myeloid infection is sparse at steady state [68] , inefficient ex vivo and not prominent in disease states, it is important for host entry, lymph node colonization [69] and systemic spread [27] . Myeloid cells engulf environmental antigens at many mucosal surfaces [70] [71] [72] and this can be extensive [73] . Therefore myeloid contributions to human γ-herpesvirus infections may be under-estimated.
The amount of antibody attached to shed virions is unknown, but salivary antibody has clear potential to affect tropism [74, 75] . Membrane fusion blocks or strong IgA responses might block host entry, because all infection requires fusion and mucosal IgA has a strong outward flux. However MuHV-4 elicits little post-binding neutralization [76] and little IgA [77] ; antibody protects by effector recruitment [78] and poorly blocks host entry [59] . MuHV-4 is adapted to B cell physiology like EBV [79] but also to myeloid physiology, which encompasses the capture, transport and transfer of environmental antigens to B cells. Such adaptation is unlikely to be unique. Therefore γ-herpesvirus infection control strategies must consider not just the defensive functions of myeloid cells, but also their potential vulnerabilities.
Materials and Methods
Mice
C57BL/6J, BALB/c (Harlan UK or Animal Resources Centre, WA), LysM-cre [43] (Jackson Laboratories), Ai6-ZSgreen1 [44] , CD11c-cre [80] and CD169-DTR mice [47] were bred in the Department of Pathology, Cambridge or the Herston Medical Research Centre, Queensland. For infection, 6-12 week old mice were anesthetized with isoflurane and virus (30μl) pipetted onto the nares, from where it was inhaled. For luciferase imaging, mice were injected i.p. with 2mg D-luciferin, anesthetised with isoflurane and monitored for light emission with a chargecoupled device camera (IVIS lumina, Caliper Life Sciences). CD169-DTR mice (CD169 +/DTR )
were depleted of CD169 + cells by i.p. diphtheria toxin (2μg / mouse) (Sigma-Aldrich).
Ethics statement
Animal experiments were approved by the Cambridge University ethical review board, the UK Home Office (Project Licence 80/2538), and the University of Queensland animal ethics committee.
Cells
BHK-21 cells (ATCC CCL-10), RAW-264 (ATCC TIB-71), 3T3-50 [15] , NMuMG (ATCC CRL-1636) and 3T3-cre cells [24] were grown in Dulbecco's Modified Eagle's Medium with 2mM glutamine, 100IU/ml penicillin, 100μg/ml streptomycin, and 10% fetal calf serum (PAA laboratories). Macrophages were recovered from mice by post-mortem bronchial or peritoneal lavage, then adhered to tissue culture plastic (1h, 37°C) and washed in medium to remove contaminating B cells. The remaining cells were >95% CD68 + .
Viruses
All viruses were derived from a BAC-cloned MuHV-4 genome [81] with an HCMV IE1 promoter-driven eGFP expression cassette. In some experiments this loxP-flanked cassette was retained to identify infected cells by eGFP expression; for fluorochrome-switching [26] , luciferase-expressing [15] and EF1α promoter driven eGFP viruses [82] it was removed by passage in 3T3-cre cells. ORF50 -MuHV-4 was grown and titered in 3T3-ORF50 cells, with ORF50 expression induced by doxycycline (1μg/ml). Herpes simplex virus type-1 (HSV-1) expressing eGFP from an HCMV IE1 promoter was grown and titered on BHK-21 cells [83] . MuHV-4 was recovered from infected cell supernatants by ultracentrifugation (13,000 x g, 2h).
Any cell debris was removed by low speed centrifugation (500 x g, 5min) and filtration (0.45μm). HSV-1 was recovered from infected cells by low speed centrifugation (500 x g, 10min) then sonicated (3 x 1min). Cell-associated MuHV-4 was prepared as for HSV-1 by centrifugation and sonication of infected BHK-21 cells. All virus stocks were titered by plaque assay and stored at-70°C.
Infectivity assays
Infectious virus was measured by plaque assay [24] 
Immunofluorescence
Organs were fixed in 1% formaldehyde / 10mM sodium periodate / 75mM L-lysine (24h, 4°C), equilibrated in 30% sucrose (18h, 4°C), then frozen in OCT. 9μm sections were air dried (1h, 23°C), blocked with 0.3% Triton X-100 / 5% normal goat serum (1h, 23°C), then incubated (18h, 4°C) with combinations of primary antibodies to eGFP (rabbit pAb, Abcam), mCherry (rabbit pAb, Badrilla), B220 (rat mAb RA3-6B2, Abcam), CD11c (hamster mAb N418, Abcam), CD169 (rat mAb 3D6.112, Abcam), CD206 (rat mAb MR5D3, Santa Cruz), unsulfated heparan (mouse mAb NAH46, Seikagaku Corporation), sulfated heparan (mouse mAb 10E4, Seikagaku Corporation), CD68 (rat mAb FA-11, Biolegend), PDP (goat pAb, R&D Systems), surfactant protein C precursor (goat pAb, Santa Cruz Biotechnology), MAC-2 (rat mAb M3/38, eBioscience), GR-1 (rat mAb RB6-8C5, R&D Systems), myeloperoxidase (goat pAb, R&D Systems), F4/80 (rat mAb CI:A3-1, Serotec), collagen IV (rabbit pAb, Abcam), HSV-1 (rabbit pAb, Abcam), and MuHV-4 (rabbit pAb). After incubation with primary antibodies (16h, 23°C), sections were washed x3 in PBS, incubated (1h, 23°C) with Alexa633-conjugated goat anti-rat IgG pAb, streptavidin-conjugated Alexa568 and Alexa488-or 568-conjugated goat anti-rabbit IgG pAb (Invitrogen), washed x3 in PBS, and mounted in Prolong Gold + DAPI. Fluorescence was visualised with a Leica TCS SP5 or Zeiss LSM 510 confocal microscope or a Nikon epifluorescence microscope, and analysed with ImageJ.
ELISA
MuHV-4 virions were disrupted with 0.05% Triton-X100 in 50mM sodium carbonate pH = 8.5, and coated (18h, 4°C) onto Maxisorp ELISA plates (Nalge Nunc). The plates were washed x3 in PBS / 0.1% Tween-20, blocked with 2% bovine serum albumin in PBS / 0.1% Tween-20, incubated with 3-fold dilutions of serum from MuHV-4-exposed mice (1h, 23°C), washed x4 in PBS / 0.1% Tween-20, incubated (1h, 23°C) with alkaline phosphatase-conjugated goat anti-mouse IgG-Fc pAb (Sigma Chemical Co.), washed x5, and developed with nitrophenylphosphate substrate (Sigma). Absorbance was read at 405nm (Biorad), and the presence of a MuHV-4-specific response determined by comparison with sera from age-matched, uninfected controls.
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